Recombinant human IL-26 facilitates the innate immune response to endotoxin in the bronchoalveolar space of mice in vivo

PLoS One. 2017 Dec 5;12(12):e0188909. doi: 10.1371/journal.pone.0188909. eCollection 2017.

Abstract

Interleukin (IL)-26 is released in response to bacterial endotoxin (LPS) in the bronchoalveolar space of humans in vivo and it may potentiate neutrophil chemotaxis by enhanced IL-26 receptor stimulation. However, the effects of extracellular IL-26 protein on the innate immune response in the lungs in vivo remain unknown. Here, we characterized these effects of IL-26 on a wide range of aspects of the innate immune response to LPS in different compartments of the lungs in vivo over time. We administrated recombinant human (rh) IL-26 protein in the bronchoalveolar space using intranasal instillation in a mouse in vivo model, with and without prior instillation of LPS. We verified gene expression of the IL-26 receptor complex in mouse lungs and observed that, after instillation of LPS, rhIL-26 increases the phosphorylation of STAT3, a signaling molecule of the IL-26 receptor complex. We also observed that rhIL-26 exerted additional stimulatory and inhibitory actions that are compartment- and time-dependent, resulting in alterations of cytokines, proteinases, tissue inflammation and the accumulation of innate effector cells. Without the prior instillation of LPS, rhIL-26 exerted time-dependent effects on total gelatinase activity but few other effects. Most important, after instillation of LPS, rhIL-26 cleared inflammatory cells from local tissue and increased the accumulation of innate effector cells in the bronchoalveolar space. Tentatively, rhIL-26 may facilitate the innate immune response towards the bronchoalveolar space in vivo and represents a potential target for therapy in lung disorders involving the innate immune response.

MeSH terms

  • Animals
  • Bronchi / drug effects*
  • Bronchi / immunology
  • Bronchoalveolar Lavage Fluid
  • Cytokines / biosynthesis
  • Humans
  • Immunity, Innate / drug effects*
  • Interleukins / pharmacology*
  • Lipopolysaccharides / pharmacology*
  • Mice
  • Mice, Inbred BALB C
  • Peroxidase / metabolism
  • Phosphorylation
  • Pulmonary Alveoli / drug effects*
  • Pulmonary Alveoli / immunology
  • RNA, Messenger / genetics
  • Recombinant Proteins / pharmacology

Substances

  • Cytokines
  • IL26 protein, human
  • Interleukins
  • Lipopolysaccharides
  • RNA, Messenger
  • Recombinant Proteins
  • Peroxidase

Grants and funding

This study was funded by the Swedish Heart-Lung Foundation (AL), the Swedish Institute (AL), the Swedish Research Council (AL and LOC), King Gustaf V’s and Queen Victoria’s Freemason Research Fund (AL), federal funding from Karolinska Institutet (AL) and from ALF (SLL) and LUA (VGR) grants (AL for both). This publication is a result of Aihua Bao’s postdoctoral research work at Karolinska Institutet, made possible by the support of Chinese Scholarship Council (AB and AL) and the Swedish Institute, as well as the Shanghai Municipal Commission of Health and Family Planning grant (AB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.